<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Survodutide: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-survodutide</link>
    <atom:link href="https://greypeptides.com/changes/survodutide.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Survodutide on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>New guide: What lab testing shows</title>
      <link>https://greypeptides.com/testing/#c-survodutide</link>
      <guid isPermaLink="false">greypeptides-changes-survodutide-guide-/testing/#c-survodutide</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.</description>
    </item>
    <item>
      <title>News: SYNCHRONIZE-2: Survodutide Reaches 13.1% Weight Loss in Type 2 Diabetes, and 18% Stopped for Side Effects</title>
      <link>https://greypeptides.com/news/synchronize-2-survodutide-type-2-diabetes/</link>
      <guid isPermaLink="false">greypeptides-changes-survodutide-news-synchronize-2-survodutide-type-2-diabetes</guid>
      <pubDate>Thu, 01 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>SYNCHRONIZE-2: Survodutide Reaches 13.1% Weight Loss in Type 2 Diabetes, and 18% Stopped for Side Effects</description>
    </item>
    <item>
      <title>News: SYNCHRONIZE-1: Survodutide Hits 16.6% Weight Loss in Phase 3</title>
      <link>https://greypeptides.com/news/synchronize-1-survodutide-phase3-obesity/</link>
      <guid isPermaLink="false">greypeptides-changes-survodutide-news-synchronize-1-survodutide-phase3-obesity</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>SYNCHRONIZE-1: Survodutide Hits 16.6% Weight Loss in Phase 3</description>
    </item>
  </channel>
</rss>
